SOLIGENIX, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
SOLIGENIX, INC. (SNGX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $1.45 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2024-08-09
- 2024-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.45M.
- 2024-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.45M.
- 2023-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $128.09K.
- 2023-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $191.44K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2024-06-30 | $1.45M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $2.45M 10-Q · filed 2024-05-10 |
| 2023-09-30 | $128.09K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $191.44K 10-Q · filed 2023-08-21 |
| 2023-03-31 | $6.40M 10-Q · filed 2023-05-15 |
| 2022-09-30 | $213.49K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $426.98K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $638.15K 10-Q · filed 2022-05-13 |
| 2021-09-30 | $452.19K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |